InvestorsHub Logo

monkeybuilt

02/26/15 12:26 PM

#30821 RE: BiotechValues #30818

Mostly agree, however, INSPECT® has already been commercialized.

SGLB can't have much in the way of sales until the trigger is pulled on projects that involve printing volume "production" parts since that is the only area that INSPECT® offers any value. No one is really doing it yet. GE is leading the charge and needs to pull the trigger soon but haven't quite yet.

The vast majority of today's 3D printing revolves around prototyping, but that is starting to shift toward production. It is during this transition that SGLB offers tremendous value. Until it happens...we wait.

Also, DEFORM® is due any day now ;-)

jpi

02/26/15 12:30 PM

#30822 RE: BiotechValues #30818

They can attend and host all the additive conferences in the world and it won't matter if they don't fully commercialize PrintRite3D



Precisely the point...I am aware that the full package is incomplete at this time but as for future adoption, I don't think they would carry them if they were not working toward a viable solution?

I know you have attended and spoke at a few conferences. From what you are seeing, are they still leading in the IPQA arena for metal additive more specifically for critical parts?

This is all pps aside...I ain't sweatin it.